

# Lamoxsan 150 mg/ml suspension for injection for cattle and pigs

Authorised

- Amoxicillin

## Product identification

**Medicine name:**

Lamoxsan 150 mg/ml suspension for injection for cattle and pigs

---

**Active substance:**

Amoxicillin

---

**Target species:**

Cattle

Pig

---

**Route of administration:**

Intramuscular use

---

## Product details

**Active substance and strength:**

Amoxicillin

150.00 milligram(s) / 1.00 millilitre(s)

---

**Pharmaceutical form:**

Suspension for injection

---

**Withdrawal period by route of administration:****Intramuscular use:**

- 

**Cattle**

- Meat and offal. 18 day
- Milk. 72 hour

- 

**Pig**

- Meat and offal. 20 day

---

**Anatomical therapeutic chemical veterinary (ATCvet) codes:**

QJ01CA04

---

**Legal status of supply:**

Veterinary medicinal product subject to veterinary prescription

---

**Authorisation status:**

Valid

---

**Authorised in:**

Belgium

---

**Package description:**

Clear PET vial of 100 ml closed with type I laminated chlorobutyl rubber stopper and aluminium cap in a carton box.

Clear PET vial of 250 ml closed with type I laminated chlorobutyl rubber stopper and aluminium cap in a carton box.

Clear type II glass vial of 100 ml closed with type I laminated chlorobutyl rubber stopper and aluminium cap in a carton box.

Clear type II glass vial of 250 ml closed with type I laminated chlorobutyl rubber stopper and aluminium cap in a carton box.

---

## Additional information

**Entitlement type:**

Marketing Authorisation

---

**Legal basis of product authorisation:**

Generic application (Article 18 of Regulation (EU) 2019/6)

---

**Marketing authorisation holder:**

Alfasan Nederland B.V.

---

**Marketing authorisation date:**

13/06/2024

---

**Manufacturing sites for batch release:**

Alfasan Nederland B.V.

---

**Responsible authority:**

Federal Agency For Medicines And Health Products

---

**Authorisation number:**

This information is not available for this product.

---

**Date of authorisation status change:**

13/06/2024

---

**Reference member state:**

Netherlands

---

**Procedure number:**

NL/V/0391/001

---

**Concerned member states:**

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland  
France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania  
Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain  
Sweden United Kingdom (Northern Ireland)

---

**Generic of:**

600000004401

---

To consult adverse reactions on veterinary medicinal products please go to  
[www.adrreports.eu/vet](http://www.adrreports.eu/vet)

## Documents

### Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

### Labelling

This document does not exist in this language (English). You can find it in another language below.

### Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

### Combined File of all Documents

NLV0391001DC\_DCP\_Lamoxsan final PuAR.pdf